BioLife Solutions (BLFS) to Release Quarterly Earnings on Thursday

BioLife Solutions (NASDAQ:BLFS) will likely be posting its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect BioLife Solutions to post earnings of $0.01 per share and revenue of $25.6640 million for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

BioLife Solutions Trading Up 1.7%

Shares of BLFS stock traded up $0.36 during mid-day trading on Tuesday, reaching $21.45. The stock had a trading volume of 141,901 shares, compared to its average volume of 400,128. The company has a market cap of $1.05 billion, a P/E ratio of -195.07 and a beta of 1.97. BioLife Solutions has a 12-month low of $17.86 and a 12-month high of $29.62. The business has a 50-day simple moving average of $20.41 and a 200 day simple moving average of $23.46.

Analysts Set New Price Targets

BLFS has been the topic of a number of recent research reports. Northland Securities set a $34.00 target price on BioLife Solutions in a research note on Monday, January 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioLife Solutions in a research report on Monday, April 20th. Wall Street Zen upgraded shares of BioLife Solutions from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Finally, Zacks Research upgraded BioLife Solutions from a “hold” rating to a “strong-buy” rating in a report on Friday, January 23rd. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $32.00.

Insider Buying and Selling

In other BioLife Solutions news, insider Karen A. Foster sold 96,923 shares of the company’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $20.15, for a total transaction of $1,952,998.45. Following the completion of the sale, the insider directly owned 113,742 shares in the company, valued at $2,291,901.30. This represents a 46.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders sold 99,641 shares of company stock worth $2,009,000 in the last ninety days. Corporate insiders own 2.20% of the company’s stock.

Institutional Trading of BioLife Solutions

A number of institutional investors and hedge funds have recently bought and sold shares of BLFS. T. Rowe Price Investment Management Inc. raised its holdings in BioLife Solutions by 27.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 5,180,824 shares of the medical equipment provider’s stock valued at $125,273,000 after buying an additional 1,113,972 shares during the period. Invesco Ltd. grew its stake in BioLife Solutions by 9.2% during the fourth quarter. Invesco Ltd. now owns 3,932,191 shares of the medical equipment provider’s stock worth $95,080,000 after buying an additional 332,747 shares during the period. State Street Corp increased its position in shares of BioLife Solutions by 3.4% in the fourth quarter. State Street Corp now owns 1,505,593 shares of the medical equipment provider’s stock worth $36,405,000 after acquiring an additional 49,028 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of BioLife Solutions by 11.3% in the second quarter. Ameriprise Financial Inc. now owns 1,080,371 shares of the medical equipment provider’s stock worth $23,271,000 after acquiring an additional 109,959 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of BioLife Solutions by 2.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,025,170 shares of the medical equipment provider’s stock valued at $24,791,000 after acquiring an additional 21,787 shares during the period. Institutional investors and hedge funds own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.